← 홈

Antibody

1,830개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 1,830개
AntibodystaleRochePhase 3

trastuzumab (Herceptin, Paclitaxel + Trastuzumab)

HER2-positive Breast Cancer · HER2

#HER2#Antibody#Phase3#항체#면역항체+3
효능 ORR 69.3%임상시험 31상태 RECRUITING
AntibodystaleMerckPhase 2

pembrolizumab (Keytruda, Pembrolizumab - 4 cycle)

Breast Neoplasms; Breast Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
효능 ORR 84%임상시험 31상태 RECRUITING
AntibodystaleMerckPhase 2

pembrolizumab (Keytruda, Pembrolizumab - 8 cycle)

Breast Neoplasms; Breast Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
효능 ORR 25%임상시험 31상태 RECRUITING
AntibodystaleRochePhase 2

trastuzumab (Herceptin, Pertuzumab + trastuzumab)

Elderly Metastatic Breast Cancer Population · Elderly Metastatic Breast Cancer Populat

#ElderlyMetastaticBreastCancerPop#Antibody#Phase2#항체#면역항체+2
효능 ORR 69.3%임상시험 31상태 ACTIVE
AntibodystaleRochePhase 2

trastuzumab (Herceptin, Pertuzumab and Trastuzumab)

Breast Neoplasms; Breast Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
효능 ORR 69.3%임상시험 31상태 RECRUITING
AntibodystaleRochePreclinical

Mabthera®, Roche Pty Ltd, Basel, Switzerland (Rituximab, Rituximab (Mabthera®, Roche Pty Ltd, Basel, Switzerland))

Non Hodgkin Lymphoma · Non Hodgkin Lymphoma

#NonHodgkinLymphoma#Antibody#Preclinical#항체#면역항체+2
효능 ORR 4%임상시험 31상태 ACTIVE
AntibodyBiologicstaleSeagen Inc.Phase 2

anti-CD30 mAb (SGN-30, SGN-30 (anti-CD30 mAb))

Anaplastic Large-Cell Lymphoma · CD30

#CD30#Antibody#Phase2#항체#면역항체+3
효능 ORR 89.5%임상시험 31상태 ACTIVE
AntibodyRochePhase 3

atezolizumab (Tecentriq, Tiragolumab and Atezolizumab)

Head and Neck Neoplasms; MSI-H Cancer · Cancer

#Cancer#Antibody#Phase3#항체#면역항체+5
효능 ORR 77.3%임상시험 31상태 RECRUITING
AntibodystaleRochePhase 2

trastuzumab (Herceptin, Trastuzumab and Pertuzumab)

Lymphoma, Non-Hodgkin; Multiple Myeloma · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#Antibody#Phase2#항체#면역항체+5
효능 ORR 69.3%임상시험 31상태 RECRUITING
AntibodystaleRochePhase 3

trastuzumab (Herceptin, Trastuzumab+ chemotherapy)

HER2-positive Advanced Breast Cancer · HER2

#HER2#Antibody#Phase3#항체#면역항체+3
효능 ORR 88.6%임상시험 31상태 RECRUITING
AntibodystaleJazz PharmaceuticalsPhase 2

Zanidatamab (ZW25, ZW25 (Zanidatamab))

HER2+/HR+ Breast Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
효능 ORR 34%임상시험 31상태 ACTIVE
AntibodyRocheVedotin Plus an Anti-CD20 M…Phase 2

Zanubrutinib and Rituximab (Zanubrutinib and Rituximab)

Untreated Mantle Cell Lymphoma · Mantle Cell Lymphoma

#MantleCellLymphoma#Antibody#Phase2#항체#면역항체+5
효능 ORR 48.7%임상시험 31상태 RECRUITING
AntibodystaleJiangsu Hansoh Pharmaceutical C…Phase 2

adebrelimab and chemotherapy (adebrelimab and chemotherapy)

Efficacy and Safety of Neoadjuvant Immunotherapy for Small Cell Lung Cancer · Efficacy and Safety of Neoadjuvant Immun

#EfficacyandSafetyofNeoadjuvantIm#Antibody#Phase2#항체#면역항체+2
임상시험 31상태 RECRUITING
AntibodystaleBiogenPhase 2

90-Y-ibritumomab tiuxetan (90-Y-ibritumomab tiuxetan)

Lymphoma · Lymphoma

#Lymphoma#Antibody#Phase2#항체#면역항체+2
효능 ORR 89%임상시험 30상태 ACTIVE
AntibodystaleQuantumLeap Healthcare Collabor…Phase 2

AMG 479 (AMG 479, Ganitumab, AMG 479 (Ganitumab) plus Metformin)

Breast Neoplasms; Breast Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
효능 ORR 27%임상시험 30상태 RECRUITING
AntibodyRochevedotin and anti-CD19 chime…Phase 2

Acalabrutinib combination with Rituximab (Acalabrutinib combination with Rituximab)

Mantle-cell Lymphoma · Mantle-cell Lymphoma

#Mantle-cellLymphoma#Antibody#Phase2#항체#면역항체+4
효능 ORR 66.4%임상시험 30상태 RECRUITING
AntibodyTang-Du Hospitalvedotin (RC48) in combinati…Phase 2

Adebrelimab combined with Apatinib (Adebrelimab combined with Apatinib)

SCLC · SCLC

#SCLC#Antibody#Phase2#항체#면역항체+4
임상시험 30상태 RECRUITING
AntibodystaleRegeneronPhase 2

aflibercept (Eylea, VEGF Trap-Eye, Eylea HD, Aflibercept IVT)

Neovascular (Wet) Age-Related Macular Degeneration · Diabetic Macular Edema

#DiabeticMacularEdema#Antibody#Phase2#항체#면역항체+3
효능 ORR 11.4%임상시험 30상태 RECRUITING
AntibodyNantes University HospitalPreclinical

Azathioprine + infliximab (Azathioprine + infliximab)

Crohn Disease · Crohn Disease

#CrohnDisease#Antibody#Preclinical#항체#면역항체+3
효능 ORR 6%임상시험 30상태 RECRUITING
AntibodystaleRochePhase 2

Bendamustine + Rituximab (Bendamustine + Rituximab)

Marginal Zone Lymphoma(MZL) · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#Antibody#Phase2#항체#면역항체+3
효능 ORR 95%임상시험 30상태 RECRUITING

9 / 92 페이지

← 이전다음 →